首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1923篇
  免费   109篇
  国内免费   11篇
耳鼻咽喉   7篇
儿科学   46篇
妇产科学   25篇
基础医学   203篇
口腔科学   19篇
临床医学   127篇
内科学   601篇
皮肤病学   73篇
神经病学   131篇
特种医学   44篇
外科学   327篇
综合类   21篇
一般理论   1篇
预防医学   75篇
眼科学   42篇
药学   149篇
中国医学   3篇
肿瘤学   149篇
  2023年   20篇
  2022年   24篇
  2021年   67篇
  2020年   40篇
  2019年   73篇
  2018年   43篇
  2017年   50篇
  2016年   51篇
  2015年   54篇
  2014年   100篇
  2013年   131篇
  2012年   195篇
  2011年   220篇
  2010年   87篇
  2009年   90篇
  2008年   147篇
  2007年   103篇
  2006年   133篇
  2005年   104篇
  2004年   88篇
  2003年   55篇
  2002年   49篇
  2001年   17篇
  2000年   11篇
  1999年   7篇
  1998年   7篇
  1997年   7篇
  1996年   3篇
  1995年   9篇
  1994年   2篇
  1993年   4篇
  1992年   3篇
  1991年   7篇
  1990年   6篇
  1989年   2篇
  1988年   3篇
  1986年   5篇
  1985年   4篇
  1984年   2篇
  1982年   2篇
  1981年   3篇
  1980年   2篇
  1979年   2篇
  1976年   1篇
  1969年   1篇
  1968年   1篇
  1964年   2篇
  1958年   1篇
  1945年   1篇
  1929年   1篇
排序方式: 共有2043条查询结果,搜索用时 15 毫秒
971.
972.
1-(Arylsulfonyl)-2-[(methoxycarbonyl)sulfenyl]-1-methylhydrazines, with the potential to function as biological methylating agents, were synthesized and evaluated as antineoplastic agents against the L1210 leukemia and the B16 melanoma in mice. All of the compounds of this class had significant activity against the B16 melanoma, with the most active compound, 2-[(methoxycarbonyl)sulfenyl]-1-methyl-1-[(4- methylphenyl)sulfonyl]hydrazine, producing percent T/C values for B16 melanoma tumor bearing mice of between 182 and 232 at dosage levels of from 12.5 to 50 mg/kg daily for 6 consecutive days. In contrast to the related class of agents, the N,N'-bis(sulfonyl)hydrazines reported earlier by this laboratory,1 the 1-(arylsulfonyl)-2-[(methoxycarbonyl)sulfenyl]-1-methylhydrazines were found to be inactive against the L1210 leukemia in vivo.  相似文献   
973.
974.
975.
976.
A 5-year-old boy with stenosed left pulmonary artery following total correction of tetralogy of Fallot underwent surgical pulmonary arterioplasty through a left anterolateral thoracotomy on a normothermic perfused heart under cardiopulmonary bypass. We found this to be a convenient approach, and recommend it for correction of this lesion in the absence of gross pulmonary regurgitation and right ventricular outflow tract dilatation.  相似文献   
977.
Tumor growth is not solely a consequence of autonomous tumor cell properties. Rather, tumor cells act upon and are acted upon by their microenvironment. It is tumor tissue biology that ultimately determines tumor growth. Thus, we developed a compound library screen for agents that could block essential tumor-promoting effects of the glioblastoma (GBM) perivascular stem cell niche (PVN). We modeled the PVN with three-dimensional primary cultures of human brain microvascular endothelial cells in Matrigel. We previously demonstrated stimulated growth of GBM cells in this PVN model and used this to assay PVN function. We screened the Microsource Spectrum Collection library for drugs that specifically blocked PVN function, without any direct effect on GBM cells themselves. Three candidate PVN-disrupting agents, Iridin, Tigogenin and Triacetylresveratrol (TAR), were identified and evaluated in secondary in vitro screens against a panel of primary GBM isolates as well as in two different in vivo intracranial models. Iridin and TAR significantly inhibited intracranial tumor growth and prolonged survival in these mouse models. Together these data identify Iridin and TAR as drugs with novel GBM tissue disrupting effects and validate the importance of preclinical screens designed to address tumor tissue function rather than the mechanisms of autonomous tumor cell growth.  相似文献   
978.

Background

In the treatment of rectal cancers several randomized trials have demonstrated benefits of neoadjuvant chemoradiotherapy (NACRT) in downstaging as well as survival among these patients. We investigated the patient and tumor related variables dictating the outcomes in these patients.

Methods

Biopsy proven treatment naive 182 rectal cancer patients underwent NACRT from June 2006 to December 2010. The entire patients received long course conventionally fractionated external beam radiotherapy with concurrent oral Capecitabine. At 6 weeks from completion of NACRT clinico-radiological assessment was carried out for surgical feasibility. All patients were given postoperative adjuvant chemotherapy either single agent or multi drug regimen depending upon biopsy report.

Results

Among 182 patients, 131 (72%) underwent surgery and initial T stage and signet ring cell morphology were major determinant of operability. Among the 131 operated patients at median follow up of 36 months, 94 (72%) are alive and disease free. With a median follow up of 42 months the 5-year disease free survival (DFS) and overall survival (OS) was 60% and 77%. The majority of the failures were distal but with more advanced disease at presentation both local and distal failures were similar. While assessing survival by multivariate analysis patients having positive nodes post-surgery had a significantly poorer DFS (P=0.001), while signet ring cell morphology and pre-treatment carcino-embryonic antigen (CEA) levels strongly influenced OS (P=0.03).

Conclusions

The outcome of our patients were similar to World Literature and signet ring cell morphology, pre-treatment CEA level, and pathological nodal staging all were influential in determining survival. Besides this, the study also highlights the fact that tumours with signet ring cell morphology appearing in younger population with poor survival needs prospective evaluation for more intense CRT regimen and aggressive surgical resections.  相似文献   
979.
Poludasu SS  Vladutiu P  Lazar J 《Angiology》2008,59(1):114-116
Migration of endovascular stents is a rare problem but can be fatal. We report an unusual case of an endovascular stent in the right ventricular outflow tract, which migrated from superior vena cava in a patient with superior vena cava syndrome.  相似文献   
980.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号